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Abstract
Neurodegenerative diseases such as Huntington disease are devastating disorders with no therapeutic approaches to
ameliorate the underlying protein misfolding defect inherent to poly-glutamine (polyQ) proteins. Given the mounting
evidence that elevated levels of protein chaperones suppress polyQ protein misfolding, the master regulator of protein
chaperone gene transcription, HSF1, is an attractive target for small molecule intervention. We describe a humanized yeast-
based high-throughput screen to identify small molecule activators of human HSF1. This screen is insensitive to previously
characterized activators of the heat shock response that have undesirable proteotoxic activity or that inhibit Hsp90, the
central chaperone for cellular signaling and proliferation. A molecule identified in this screen, HSF1A, is structurally distinct
from other characterized small molecule human HSF1 activators, activates HSF1 in mammalian and fly cells, elevates protein
chaperone expression, ameliorates protein misfolding and cell death in polyQ-expressing neuronal precursor cells and
protects against cytotoxicity in a fly model of polyQ-mediated neurodegeneration. In addition, we show that HSF1A
interacts with components of the TRiC/CCT complex, suggesting a potentially novel regulatory role for this complex in
modulating HSF1 activity. These studies describe a novel approach for the identification of new classes of pharmacological
interventions for protein misfolding that underlies devastating neurodegenerative disease.
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Introduction
Neuronal tissues are exquisitely sensitive to defective protein
folding, and the accumulation of misfolded proteins is proteotoxic
due to dominant effects of insolubility, inappropriate intermolec-
ular interactions, and long half-lives. Protein misfolding is
associated with neurodegenerative diseases that include Parkinson
disease, amyotropic lateral sclerosis (ALS), transmissible spongi-
form encephalopathies (prion diseases), and other devastating
diseases [1]. Hereditary protein conformational disorders are
characterized by coding region trinucleotide expansions resulting
in the insertion of poly-glutamine (polyQ) tracts that adopt b-sheet
structures and that are prone to incorrect folding and aggregation
[2]. To date, nine hereditary gain-of-function disorders including
Huntington disease, dentatorubral-pallidoluysian atrophy, spino-
bulbar muscular atrophy, as well as six forms of spinocerebellar
ataxia have been linked to polyQ expansions [2]. Although studies
have suggested that amyloid formation observed in these states is
intrinsic to the disease pathology, recent investigations suggest that
the soluble oligomeric precursors of the large aggregates are the
neurotoxic form [3]. Although there is no known cure for these
devastating diseases, the ability to stabilize misfolded proteins into
their native conformation would likely prevent the neuronal
proteotoxicity that is observed in Huntington disease and other
protein conformational disorders.
A variety of individual protein chaperones and cochaperone
complexes function to fold, process, and degrade proteins, thereby
playing a central role in cellular protein homeostasis [4].
Experiments in cell and animal models of neurodegenerative
disease demonstrate that increased levels of individual protein
chaperones such as Hsp70, Hsp40, or Hsp27 can significantly
suppress protein aggregation, increase protein solubility and
turnover, and ameliorate neuronal loss [5–16]. Additional studies
suggest that simultaneous increases in Hsp70 and Hsp40 can
synergize the suppression of polyQ-mediated neuronal degener-
ation [8,9,13]. Because most metazoan chaperones stabilize, but
do not disaggregate misfolded proteins, these results are consistent
with the oligomeric precursors of amyloid fibrils being toxic to
neurons, rather than the aggregates themselves [3,14,15,17].
In eukaryotic cells, multiple genes encoding protein chaperones
are coordinately transcriptionally activated in response to
proteotoxic conditions, such as acute increases in temperature,
by the heat shock transcription factor 1 (HSF1) protein and
cis-acting promoter sequences called heat shock elements (HSEs)
[18–20]. As such, protein chaperones are often referred to as heat
shock proteins, or Hsps. Although the mechanisms for HSF1
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in response to stress that involves the interconversion of an inactive
cytoplasmic monomer to a homotrimer, nuclear accumulation,
DNA binding to HSEs, hyperphosphorylation, and target gene
trans-activation [21]. Studies suggest that under low proteotoxic
stress conditions, HSF1 is largely an inactive cytoplasmic
monomer that is bound to Hsp90, Hsp70, and other proteins in
a repressive complex [22,23]. It is thought that under stress
conditions, HSF1 dissociates from this complex, allowing homo-
multimerization and activation. Although the association of HSF1
with protein chaperones is one mechanism for its regulation, HSF1
is also thought to engage in intramolecular coiled-coil interactions
that maintain the monomeric state and point mutations in these
coiled-coil domains (leucine zippers) cause constitutive multi-
merization when expressed in mammalian cells [24]. Studies also
suggest that HSF1 has intrinsic stress-sensing capacity, as both
Drosophila and mammalian HSF1 can be converted from a
monomer to a homotrimer in vitro in response to thermal or
oxidative stress [25–27].
Previous reports demonstrate that the conversion of HSF1 to
the high-affinity DNA binding homotrimer is not robust in
neuronal cells [28]. Although the precise mechanisms underlying
this defect in HSF1 activation are not clear, this could, in part,
explain the selective sensitivity of neuronal cells in neurodegen-
erative diseases in which misfolded proteins are expressed in all
tissues [28]. A recent report demonstrated that a cellular model
and a mouse model of Huntington disease expressing a
constitutively active form of human HSF1 exhibited reduced
polyglutamine protein aggregation [5]. Furthermore, the expres-
sion of activated HSF1 in nonneuronal tissues prolonged the
lifespan of this mouse model of Huntington disease. Yeast cells
harboring an HSF molecule partially defective in trans-activation
were shown to promote yeast prion formation, implying a
potential role for HSF target gene products in the prevention of
prion generation or propagation [29]. Moreover, hsf1
2/2 mice
inoculated with Rocky Mountain Laboratory prions exhibited a
shorter lifespan as compared to wild-type mice [30]. Taken
together, many studies support the value of individual protein
chaperone expression, the synergistic expression of multiple
protein chaperones, or the expression of an activated form of
HSF1, in cellular, worm, fly, and mouse models of protein
misfolding. Given the potential therapeutic role of elevated protein
chaperone levels in diseases of protein conformation and the
coordinated expression of Hsps via the action of human HSF1,
small molecule activation of human HSF1 is likely to be a
promising avenue for therapeutic intervention in neurodegener-
ative disease.
Previous screens utilizing an HSF1-dependent reporter gene as
a readout for HSF1 activation in mammalian cells have identified
activators of HSF1 [31]. However, these screens often result in the
identification of compounds that promote HSF1 activation
through the proteotoxic accumulation of unfolded proteins or
through the inhibition of Hsp90, a central chaperone involved in
cell growth, signaling, and proliferation [32–36]. As such, novel
approaches are needed to identify novel compounds that promote
HSF1 activation without the inhibition of Hsp90 or promoting the
accumulation of unfolded proteins. Here, we describe a novel
high-throughput screen to identify small molecule activators of
human HSF1 using the budding yeast Saccharomyces cerevisiae. This
screen, insensitive to established proteotoxic agents and Hsp90
inhibitors, identifies novel small molecules that activate HSF1 in
the amelioration of neurodegenerative phenotypes in metazoan
models of polyQ-based disease.
Results
A Humanized Yeast Screen for Small Molecule Activators
of HSF1
We previously demonstrated that expression of human HSF1 is
unable to suppress the viability defect of S. cerevisiae cells lacking
endogenous HSF [37]. Moreover, human HSF1 was not activated
in yeast in response to proteotoxic conditions such as heat shock
that potently activate protein chaperone expression in mammalian
cells. Biochemical analysis and functional complementation by an
HSF1 mutant that is constitutively trimerized in human cells
(HSF1LZ4m) indicated that the functional defect lies in the
inability of human HSF1 to homotrimerize in yeast cells. As HSF1
multimerization is an early and essential step in the HSF1
activation program in human cells, we utilized the inability of
human HSF1 to multimerize in yeast to screen for small molecule
activators of HSF1 that would support yeast cell growth
(Figure 1A).
For this humanized yeast screen, an S. cerevisiae strain was
created harboring a deletion of the chromosomal yeast HSF locus
(yhsfD) and which expresses a wild-type episomal copy of yeast
HSF from the galactose-inducible, glucose-repressible GAL1
promoter. Moreover, this strain expresses the wild-type human
HSF1 protein from the plasmid-borne constitutive GPD promoter.
To maximize small molecule uptake and retention, this strain was
further modified by deleting the genes encoding the drug efflux
pumps, Pdr5 and Snq2, as well as the gene encoding Erg6, an
enzyme involved in ergosterol biosynthesis, which increases the
permeability of small molecules through the plasma membrane, to
create strain DNY75 [38,39].
Strain DNY75 was grown to mid-log phase in galactose-
containing medium to drive expression of yeast HSF and then
shifted to dextrose-containing medium to extinguish expression of
yeast HSF, rendering growth entirely dependent on the activation
of human HSF1. Cells were seeded at low density to 96-well
microtiter dishes and incubated with either DMSO solvent or an
aliquot of a small molecule library. A nonbiased chemical library
of over 10,000 compounds [40], built on approximately 70 scaffold
structures, was screened at a final concentration of 10 mM for their
ability to activate HSF1-dependent growth over a 4-d period at
Author Summary
The misfolding of proteins into a toxic state contributes to
a variety of neurodegenerative diseases such as Hunting-
ton, Alzheimer, and Parkinson disease. Although no known
cure exists for these afflictions, many studies have shown
that increasing the levels of protein chaperones, proteins
that assist in the correct folding of other proteins, can
suppress the neurotoxicity of the misfolded proteins. As
such, increasing the cellular concentration of protein
chaperones might serve as a powerful therapeutic
approach in treating protein misfolding diseases. Because
the levels of protein chaperones in the cell are primarily
controlled by the heat shock transcription factor 1 [HSF1],
we have designed and implemented a pharmacological
screen to identify small molecules that can promote
human HSF1 activation and increase the expression of
protein chaperones. Through these studies, we have
identified HSF1A, a molecule capable of activating human
HSF1, increasing the levels of protein chaperones and
alleviating the toxicity of misfolded proteins in both cell
culture as well as fruit fly models of neurodegenerative
disease.
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PLoS Biology | www.plosbiology.org 2 January 2010 | Volume 8 | Issue 1 | e1000291Figure 1. HSF1A activates human HSF1 function in yeast. (A) Strategy used to identify chemical activators of human HSF1 in yeast. Yeast cells
expressing the essential yeast HSF under control of the glucose-repressible GAL1 promoter are dependent on galactose for growth. Upon shifting
cells to glucose-containing medium, the cells are dependent on activation of human HSF1 for growth. (B) Structure of HSF1A. (C) Yeast cells
expressing wild-type human HSF1 were supplemented with 10 mM HSF1A or DMSO and grown in 96-well plates for 4 d. Growth was monitored by
measuring OD600. (D) HSF1-dependence for HSF1A-mediated cell growth. Strain DNY75 expressing either human HSF1 (+HSF1) or an empty vector
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primary screen were retested in two subsequent screens at the
same concentration. Two benzyl pyrazole-based molecules, which
we have named HSF1A and HSF1C (Figure 1B and Figure S1A),
were potent activators of human HSF1-depenent yeast growth
(Figure S1B). Because HSF1A was among the most potent
activators of human HSF1-dependent yeast growth identified in
our assay, it was chosen for further investigation.
HSF1A was synthesized de novo to independently confirm its
ability to activate human HSF1-dependent yeast cell growth. As
shown in Figure 1C, HSF1A, but not DMSO solvent, stimulated
HSF1-dependent growth for strain DNY75. HSF1A was unable to
support growth of a yhsfD yeast strain in the absence of human
HSF1, confirming that HSF1A functions in an HSF1-dependent
manner to support yeast cell growth (Figure 1D). Because the
inability of HSF1 to complement the viability defect of yhsfD cells is
due to defective HSF1 multimerization in yeast, cross-linking
experiments were conducted to ascertain whether HSF1A
promotes increased HSF1 multimerization in yeast. Although
HSF1 multimers were not detected in lysates from cells treated
with DMSO, HSF1 homotrimerization is detected when yeast cells
were treated with HSF1A (Figure 1E). The constitutive trimeriza-
tion of the HSF1LZ4m protein [37] was also further increased
after HSF1A exposure, consistent with the observation that
HSF1A also enhances LZ4m-dependent yeast growth (Figure 1F).
HSF1A Coordinately Activates Protein Chaperone
Expression in Mammalian Cells
HSF1A stimulates human HSF1 multimerization in yeast and
activates human HSF1-dependent yeast cell growth. To test
whether HSF1A is able to activate HSF1 in mammalian cells,
wild-type and hsf1
2/2 mouse embryonic fibroblasts (MEFs) [41]
were incubated in the presence of DMSO solvent or increasing
concentrations of HSF1A and the expression of two protein
chaperones, Hsp70 and Hsp25, assessed by immunoblotting.
Although DMSO did not enhance protein chaperone expression,
treatment of wild-type MEFs with HSF1A resulted in the
activation of Hsp70 and Hsp25 in a dose-dependent manner
(Figure 2A). HSF1A-dependent activation of Hsp70 and Hsp25
was not detected in hsf1
2/2 cells, demonstrating that HSF1A
functions in the activation of mammalian protein chaperones
through HSF1. As previously demonstrated, wild-type MEFs
exhibited robust expression of Hsp70 and Hsp25 in response to an
acute heat shock that was absent in hsf1
2/2 MEFs. Interestingly,
although HSF1C was also able to promote Hsp70 activation in
mammalian cells, it did so at lower potency than HSF1A,
mimicking the human HSF1 activation potential of both molecules
in yeast (Figure S1C).
HSF1A-dependent activation of Hsp70 expression was also
observed in HeLa cells, confirming its ability to activate HSF1 in
human cell lines (Figure S2). Expression of Hsp70 and Hsp25 was
detected in wild-type MEFs by approximately 2 h and was
sustained for at least 15 h in the chronic presence of HSF1A
(Figure 2B). Moreover, HSF1A treatment elevated Hsp70 mRNA
levels, consistent with HSF1A activating Hsp70 gene transcription
through HSF1 (Figure 2C). Although higher concentrations of
HSF1A were used in these experiments, ELISA experiments
demonstrated dose-dependent activation of Hsp70 at lower
concentrations (Figure S3).
HSF1A Promotes HSF1 Nuclear Localization and
Hyperphosphorylation
Previous studies demonstrated that in response to proteotoxic
stress mammalian HSF1 is activated in a multistep process that
involves multimerization, nuclear accumulation, hyperpho-
sphorylation, and DNA binding to promoter HSEs to activate
protein chaperone gene expression [19–21,28]. To gain insights
into how HSF1A promotes HSF1 activation, the subcellular
localization and phosphorylation status of HSF1 was assessed in
MEFs treated with HSF1A. Although under control conditions
the majority of HSF1 was localized to the cytoplasmic fraction
with the Cu, Zn superoxide dismutase control, within 2 h after
HSF1A treatment, additional HSF1 was found in the nuclear
fraction (c-fos as control), and by 6 h and beyond, the majority
of HSF1 was nuclear (Figure 3A). As previously established, an
acute heat shock for 2 h resulted in the HSF1 being nearly
quantitatively nuclear. HSF1 that was accumulated in the
nucleus in response to HSF1A treatment had a reduced
electrophoretic mobility in SDS-PAGE as compared to that
found in the cytosolic fraction, consistent with possible
hyperphosphorylation that is observed to occur in response to
an acute heat shock [42,43]. To explore whether HSF1A
treatment results in HSF1 hyperphosphorylation, extracts were
prepared from both HSF1A-treated and heat-shocked cells in
the presence or absence of protein phosphatase inhibitors. As
shown in Figure 3B, extracts from cells incubated with HSF1A
or subjected to a 42uC heat shock and prepared in the presence
of phosphatase inhibitors showed an HSF1A-dependent reduc-
tion in electrophoretic mobility that was not present when
extracts were prepared in the absence of phosphatase inhibitors.
These results are consistent with HSF1A stimulating HSF1
phosphorylation. Although the phosphatase inhibitor-dependent
shift in HSF1 electrophoretic mobility was not as dramatic as
that for heat shock treatment, HSF1 phosphorylation occurred
in response to both treatments in parallel with expression of the
HSF1 target, Hsp70 (Figure 3B).
Previous reports have demonstrated that heat shock– or
oxidative stress–mediated activation of HSF1 in vivo or in vitro
can be abrogated by treatment with reducing agents such as DTT
[44,45]. Although HSF1A-mediated activation of human HSF1-
dependent yeast cells growth is not inhibited by DTT (Figure S4),
the ability of DTT to inhibit HSF1 activation by HSF1A was
tested in mammalian cells. DTT strongly inhibited heat shock-
induced expression of Hsp70, but had no inhibitory effect on
HSF1A-dependent activation of Hsp70 expression (Figure 3C).
These observations provide additional evidence that HSF1A
activates HSF1 in a manner that is mechanistically distinct from a
proteotoxic stress.
Previous reports suggest that conditions or small molecules
that activate or coactivate HSF1 can act synergistically with
heat stress in enhancing protein chaperone expression
[31,46,47]. The ability of HSF1A to activate protein chaperone
expression at subthreshold HSF1A concentrations, in combina-
tion with subthreshold temperatures, was assessed by immuno-
(+vector) were seeded into microtiter wells and incubated in the presence of HSF1A or DMSO solvent for 4 d and then photographed. Note that only
cells expressing human HSF1 grow in response to HSF1A. (E) Yeast strain DNY75 was grown in the presence of DMSO or 20 mM HSF1A for 18 h, and
HSF1 multimerization was evaluated by EGS cross-linking, SDS-PAGE, and immunoblotting. The positions of molecular weight markers are indicated
on the left, and circles indicating the expected migration of HSF1 monomers, dimers, and trimers are on the right. (F) Yeast cells expressing
HSF1LZ4m were supplemented with 10 mM HSF1A or DMSO and grown in 96-well plates for 4 d. Growth was monitored by measuring OD600.
doi:10.1371/journal.pbio.1000291.g001
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37uC( 3 0mMa n d5 0mM) were evaluated at a mild temperature
increase (40uC). As shown in Figure 3D, although 30 mMa n d
50 mM HSF1A are insufficient to activate Hsp70 expression at
37uC, 80 mM HSF1A significantly activated Hsp70 expression
at this temperature. Moreover, a 1-h heat shock at 42uC, but
not 40uC, followed by a 15-h recovery, was able to activate
Hsp70 expression. However, MEFs treated with 30 mMo r
50 mM HSF1A for 1 h prior to a 1-h heat shock at 40uC
strongly activated Hsp70 expression, and expression in response
to 80 mMH S F 1 Aw a sh i g h e ra t4 2 uC. Taken together, these
observations indicate that low concentrations of HSF1A can
function in concert with modest temperature increases to elevate
expression levels of mammalian chaperone proteins.
HSF1A Reduces PolyQ Aggregation and Cytotoxicity in
Neuronal Precursor Cells
Elevated expression of protein chaperones has been shown
to reduce cytotoxicity associated with a number of cellular
or metazoan models of protein conformational diseases
[5–13,48]. In many instances, this is accompanied by a
reduction in protein aggregates, supporting the notion that
protein aggregation is linked, at least in part, to cellular
toxicity [5,7,13,48]. Other reports suggest that reduction of
protein aggregates is not essential for the therapeutic effects of
protein chaperones, as some studies have shown a reduction in
cytotoxicity without an apparent change in protein aggregates
[6,8,10,11]. Since metazoan protein chaperones stabilize
misfolded proteins rather than disaggregate them [28], any
reductions in protein aggregates that have been observed in
response to protein chaperone overexpression are likely
derived from the ability of protein chaperones to stabilize the
misfolded oligomeric precursors [14,15]. However, analysis of
protein aggregate formation still serves as a useful tool for
analyzing protein chaperone function because aggregate
formation is directly dependent on the folding state of the
oligomeric precursor [17].
A cell culture model of Huntington disease was used determine
whether the ability of HSF1A to promote protein chaperone
expression can reduce the formation of protein aggregates and the
Figure 2. HSF1A activates Hsp70 expression in mammalian cells. (A) HSF1
+/+ and hsf1
2/2 MEFs were treated with DMSO solvent or
increasing concentrations of HSF1A for 15 h or heat shocked for 2 h at 42uC followed by a 15-h recovery. Total protein was analyzed for Hsp70 and
Hsp25 expression by immunoblotting. SOD1 serves as a loading control. (B) HSF1
+/+ MEF cells were treated with 80 mM HSF1A over time and Hsp70
and Hsp25 levels analyzed by immunoblotting. (C) HSF1
+/+ MEF cells were treated with 80 mM HSF1A for 6 h or heat shocked at 42uC for 2 h, and
total RNA was analyzed by RNA blotting. 18S rRNA serves as a loading control.
doi:10.1371/journal.pbio.1000291.g002
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this model, exon 1 of human Huntingtin (htt) containing 74
glutamines fused to green fluorescent protein (GFP) (httQ74-GFP)
is expressed in rat phaeochromocytoma (PC12) cells, a rat
neuronal precursor cell line, via a doxycycline-inducible promoter.
As shown in Figure 4A, HSF1A promoted Hsp70 expression in
PC12 cells, detectable by immunoblotting, at 25 mM, a concen-
tration almost 3-fold lower than that required to detect Hsp70
expression by immunoblotting in MEF cells (Figure 2A). In
addition, ELISA analysis showed that chronic exposure of PC12
cells to HSF1A at concentrations less than 25 mM promoted
Hsp70 activation (Figure S3). To ascertain whether HSF1A
pretreatment could ameliorate protein aggregation, cells were
pretreated for 15 h with either DMSO or 10 mM HSF1A prior to
a 48-h induction of httQ74-GFP expression. HttQ74-GFP
aggregates, which are resistant to SDS solubilization, were
fractionated from soluble proteins by centrifugation, and both
soluble and insoluble protein fractions assayed for abundance of
the httQ74-GFP by solubilization with urea-SDS, followed by
immunoblotting (Figure 4B). Extracts from cells pretreated with
DMSO displayed approximately 50% of the HttQ74-GFP protein
in the insoluble fraction. However, significantly less httQ74-GFP
was detected in the insoluble fraction when PC12 cells were
pretreated with 10 mM HSF1A prior to the induction of httQ74-
GFP, suggesting that HSF1A can reduce the aggregation potential
of this polyQ protein. Moreover, as previously reported,
microscopic evaluation demonstrated that overexpression of
httQ74-GFP resulted in the formation of large protein aggregates
in approximately 80% of these cells, and this was observed when
the cells were pretreated with DMSO (Figure 4C). However, when
this neuronal precursor cell line was pretreated for 15 h with
10 mM HSF1A before httQ74-GFP expression, most cells showed
diffuse, pan-cellular GFP staining and the absence of visible
protein aggregates. Quantification of these results, by counting the
number of cell containing aggregates as a function of the total
number of cells, revealed that at HSF1A concentrations as low as
2 mM, a reduced number of aggregate-containing cells were
observed (Figure 4D). The fraction of cells containing aggregates
continued to decrease in a dose-dependent manner such that
pretreatment with 12 mM HSF1A resulted in ,20% of the cells
exhibiting aggregates visible by fluorescence microscopy. When
PC12 cells were treated with HSF1A after protein aggregates had
formed, no reduction in aggregate abundance was observed
(unpublished data), supporting the notion that the protein
chaperones induced by HSF1A treatment act on the oligomeric
precursors rather than the larger aggregates.
We tested whether the ability of HSF1A to reduce protein
aggregation might also reduce the cytotoxicity associated with
polyQ protein overexpression, as previous reports have shown that
prolonged expression of httQ74-GFP results in a large percentage
of the cell population undergoing apoptosis [49]. Cells were
pretreated with 4 mM HSF1A, a concentration capable of
reducing the fraction of aggregate-containing cells by approxi-
mately 10% (Figure 4D), for 15 h prior to expression of httQ74-
GFP for 5 d. Cells pretreated with DMSO experienced a 6-fold
reduction in cell viability, whereas viability was significantly
maintained when cells were pretreated with 4 mM HSF1A prior to
httQ74-GFP induction (Figure 4E). Together, these results
demonstrate that exposure of cultured mammalian neuronal
precursor cells to HSF1A activates expression of Hsp70 and
simultaneously reduces polyQ protein aggregation and the ensuing
cell death.
HSF1A Ameliorates PolyQ-Induced Cytotoxicity in a Fly
Model of Protein Conformational Disease
The fruit fly Drosophila melanogaster has been used as an elegant
metazoan model of human neurodegenerative diseases that
include Huntington, Machado-Joseph disease (MJD) and Parkin-
son disease [6,50,51]. Although the yeast and mammalian HSF1
proteins are not highly structurally conserved, Drosophila HSF
shares strong structural conservation and is regulated via steps that
are similar to that of mammalian HSF1 [19,21]. Cultured
Drosophila S2 cells were used to test whether HSF1A is capable
of promoting Hsp70 expression, indicative of Drosophila HSF1
(dHSF1) activation. Treatment of S2 cells with a range of HSF1A
concentrations for 15 h strongly activated the expression of Hsp70
(Figure 5A). To determine whether HSF1A could promote Hsp70
expression in whole animals, W
1118 flies were maintained on food
supplemented with DMSO, 5 mM HSF1A, or as a positive control
for HSF activation via Hsp90 inhibition, 0.15 mM geldanamycin
for 3 d. Immunoblotting for Hsp70 expression from total body
protein extracts indicated that both HSF1A as well as geldana-
mycin [52] induced expression of Hsp70 in vivo (Figure 5B).
We utilized a Drosophila model of MJD to ascertain whether
HSF1A could reduce polyQ-mediated cytotoxicity in vivo. In this
strain, a truncated form of the human MJD/SCA3 protein,
containing 78 glutamines (MJDtrQ78), is expressed under the
control of the UAS promoter [51]. UAS-MJDtrQ78 flies were
crossed to flies expressing the UAS-specific Gal4 transcription
factor under control of the eye-specific gmr driver. Due to the eye-
specific expression of MJDtrQ78, cytotoxicity is manifested as
disruption of eye morphology, depigmentation, and reduction in
eye size and is observed in the progeny almost immediately after
eclosion [51]. UAS-MJDtrQ78 flies were crossed while being
maintained on food supplemented with either DMSO, HSF1A, or
17-AAG, a potent Hsp90 inhibitor that was previously demon-
strated to ameliorate polyQ expression phenotypes in this fly
model [53]. After eclosion, flies were maintained on supplemented
food for approximately 24 h, and eye phenotypes were inspected
microscopically. Similar to previous reports [51], a severe
distortion in eye morphology and depigmentation were observed
in the DMSO-treated flies (Figure 5C). However, flies fed 400 mM
HSF1A or 17-AAG exhibited a significant reduction in the
phenotypes induced by MJDtrQ78 overexpression, with eye
morphology, eye size, and pigment color resembling that observed
in control animals (Figure 5C). HSF1A treatment was unable to
ameliorate MJDtrQ78-dependent phenotypes at a nonpermissive
temperature in flies expressing a temperature-sensitive allele of
Figure 3. Features of HSF1A-dependent HSF1 activation. (A) HSF1
+/+ MEFs were treated with 80 mM HSF1A for the indicated time in hours or
heat shocked at 42uC for 2 h, and nuclear and cytoplasmic fractions were analyzed for HSF1 by immunoblotting. c-fos and SOD1 serve as nuclear (N)
and cytoplasmic (C) markers, respectively. (B) HSF1
+/+ MEFs were treated with HSF1A for 6 h or 9 h or heat shocked at 42uC for 2 h in the presence (+)
or absence (2) of phosphatase inhibitors (INHIB). (C) HSF1
+/+ MEFs were pretreated with 250 mM DTT for 1 h prior to the addition of 80 mM HSF1A for
15 h or a 2-h heat shock at 42uC followed by a 15-h recovery. For comparison purposes, the heat-shocked samples are shown at a lower exposure
than the HSF1A-treated samples. (D) HSF1
+/+ MEFs were treated with either DMSO or HSF1A (30, 50, or 80 mM) for 15 h at 37uC. For synergistic
activation of Hsp70 expression, wild-type MEFs were treated with either DMSO or HSF1A (30, 50, or 80 mM) for 1 h at 37uC prior to a 1-h heat shock at
40uC followed by a 15-h recovery period at 37uC. For control purposes, Hsp70 expression following a 1-h heat shock at 42uC, and a 15-h recovery is
shown. SOD1 serves as the protein loading control.
doi:10.1371/journal.pbio.1000291.g003
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beneficial effects through HSF1 (Figure S5). Together, these results
strongly suggest that HSF1A promotes HSF1-dependent protein
chaperone expression in metazoans and partially suppresses
cytotoxicity due to polyQ-protein expression.
HSF1A Does Not Bind Hsp90
Previous studies suggest that Hsp90 and additional cochaper-
ones exist in a heteroprotein complex that, in addition to their
central role in cellular signaling, function to repress HSF1 in the
absence of stress. In response to proteotoxic stress or pharmaco-
logical inhibitors of Hsp90, this complex dissociates, resulting in
the multimerization of HSF1 [23]. As such, we reasoned that the
inability of human HSF1 to be activated in yeast might stem from
a repressive interaction between yeast Hsp90 and human HSF1
and that HSF1A promotes HSF1 activation in yeast by disrupting
this interaction. To test this hypothesis, the efficacy of the potent
Hsp90 inhibitors geldanamycin and radicicol, in promoting
human HSF1-dependent yeast growth was evaluated. Exposure
to either 10 mM geldanamycin or 10 mM radicicol for 3 h
activated expression of the yeast HSF-dependent SSA3-lacZ
reporter gene, reflective of their previously established function
as Hsp90 inhibitors in yeast [55] (Figure S6). However, neither
geldanamycin nor radicicol were able to promote human HSF1-
dependent yeast growth under the same conditions in which they
are potent Hsp90 inhibitors (Figure 6A), suggesting that HSF1A is
Figure 4. HSF1A suppresses aggregation and cytotoxicity in a cell culture model of Huntington disease. (A) HD-Q74 PC12 cells were
incubated with increasing concentrations of HSF1A for 15 h or heat shocked for 2 h at 42uC, followed by a 15-h recovery and Hsp70 levels analyzed
by immunoblotting, with SOD1 as a loading control. (B) PC12 cells were pretreated with either DMSO or 10 mM HSF1A for 15 h and doxycycline
added to 1 mg/ml, with further incubation for 48 h. Equal amounts of the soluble and insoluble fractions were analyzed for the presence of httQ74-
GFP by immunoblotting with anti-GFP antibody. (C) Fluorescence pattern for httQ74-GFP analyzed microscopically in cells pretreated with DMSO or
HSF1A prior to induction of httQ74-GFP expression. (D) Quantification of (C) by counting the number of cells containing aggregates expressed as a
percentage of the total number of cells counted. For each treatment, approximately 800 HD-Q74 PC12 cells were evaluated. **p,0.01; ***p,0.001.
(E) PC12 cells were pretreated with 4 mM HSF1A for 15 h, before the addition of doxycycline (Dox) to 1 mg/ml followed by a 5-d incubation. Cell
viability was assayed by the XTT viability assay. ***p,0.001.
doi:10.1371/journal.pbio.1000291.g004
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HSF1 was not activated in a yeast strain that expresses ,5% of the
wild-type levels of Hsp90 [56] (unpublished data).
Many pharmacological inhibitors of Hsp90 such as geldana-
mycin and 17-AAG target the amino-terminal ATP binding
pocket of Hsp90, thereby inhibiting its chaperone function [57].
To test whether HSF1A has affinity for the Hsp90 ATP-binding
pocket, we performed competitive binding assays in vitro using a
biotinylated geldanamycin (GD-B) molecule. As shown in
Figure 6B, the high-affinity Hsp90 inhibitor 17-AAG was able to
compete with GD-B for Hsp90 binding at 1 mM and 10 mM. In
contrast, HSF1A, even at concentrations 100-fold higher than
GD-B, was unable to compete for Hsp90 binding (Figure 6B),
suggesting that HSF1A does not bind the ATP-binding pocket of
Hsp90. Because other small molecule inhibitors of Hsp90,
including celastrol, novobiocin, and EGCG, are thought to bind
Hsp90 at the carboxy-terminus [57], we ascertained whether
HSF1A could bind to Hsp90 at a region outside of the ATP-
binding pocket. To assay for HSF1A binding to Hsp90, we
generated an HSF1A-biotin conjugate (HSF1A-B) (Figure S7B)
and assayed the ability of HSF1A-B to interact with Hsp90.
Although GD-B readily interacted with Hsp90 (Figure 6C),
HSF1A-B, assayed at a concentration 10-fold higher than GD-
B, did not interact with Hsp90. Furthermore, HSF1A-B did not
interact with Hsp90 or the cochaperones Cdc37, Hop, p23, or
Hsp70, nor HSF1 itself in pull-down experiments with mamma-
lian cell extracts (unpublished data). Given that geldanamycin and
radicicol cannot promote human HSF1-dependent yeast growth
and that HSF1A does not interact with Hsp90, together these data
strongly suggest that HSF1A is not acting as an Hsp90 inhibitor in
activating HSF1 in yeast or mammalian cells.
HSF1A-Biotin Copurifies with the TRiC/CCT Complex
In order to identify potential targets of HSF1A, we utilized the
HSF1A-biotin conjugate to identify proteins that associated with
HSF1A in whole-cell extracts generated from MEF cells. SDS-
PAGE in conjunction with silver staining revealed that several
proteins between 50–60 kDa in size consistently copurified with
HSF1A-B (Figure 7A). Similar-sized proteins were also found to
associate with HSF1A-B in protein extracts generated from HeLa,
human APRE-19, as well as yeast cells (unpublished data),
suggesting that the association of HSF1A-B with these proteins is
not cell specific. To identify HSF1A-B-interacting proteins,
protein bands were excised from the gel, trypsinized to generate
peptides, and then subjected to tandem mass spectrometry (MS).
Analysis of the liquid chromatography tandem mass spectrometry
(LC-MS/MS) data using the Mascot database identified these
proteins as all eight subunits of the TRiC/CCT cytosolic
Figure 5. HSF1A promotes Hsp70 expression and reduces polyQ toxicity in fruit flies. (A) Drosophila S2 cells were treated with increasing
concentrations of HSF1A, or heat shocked (HS) at 37uC for 1 h. Hsp70 expression was analyzed by immunoblotting, with actin as a loading control. (B)
W
1118 flies were raised on food supplemented with DMSO, 5 mM HSF1A, or 0.15 mM geldanamycin (GD) for 3 d. Total protein was extracted from
flies and analyzed for Hsp70 expression by immunoblotting as for (A). (C) UAS-MJDtrQ78 flies were crossed to gmr-GAL4 flies in the chronic presence
of food supplemented with DMSO, 400 mM HSF1A, or 5 mM 17-AAG. Reductions in eye morphological defects and depigmentation, caused by polyQ-
protein expression, are observed with HSF1A and 17-AAG treatment. The lowest effective concentration of HSF1A at which reductions in defects was
observed was 400 mM. Control flies are UAS-MJDtrQ78 flies lacking the Gal4 transcription factor. These data are representative of three independent
experiments.
doi:10.1371/journal.pbio.1000291.g005
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immunoblot analysis showing that HSF1A-B copurified with
Tcp1/Cct1 and Cct8 in mammalian cell extracts (Figure 7B) as
well as yTcp1 in yeast cell extracts (Figure 7C).
HSF1A Activates Human HSF1, but Not Yeast HSF
The TRiC/CCT complex is required for the accurate folding of
cytoskeletal components including tubulin and actin as well as
most WD40 repeat-containing proteins [58]. As such, it is possible
that an interaction between HSF1A and TRiC might disrupt
TRiC function thereby promoting accumulation of misfolded
proteins and activation of HSF1 activity. To test whether HSF1A
promotes the accumulation of unfolded proteins, we assessed the
ability of HSF1A to activate the SSA3-LacZ reporter gene in yeast
since its activation is dependent on the stress-induced activation of
yeast HSF in response to the accumulation of unfolded proteins
[59]. Although a 3-h heat shock at 39uC activated expression of
the SSA3-lacZ reporter gene, no activation of this reporter was
detected after treatment with 20 mM HSF1A (Figure S8), a
concentration sufficient to promote human HSF1-dependent
growth in strain DNY75 (Figure 1C). The inability of HSF1A to
activate yeast HSF strongly suggests that HSF1A does not promote
human HSF1 activation in yeast by promoting the accumulation
of unfolded proteins but instead acts on structures or regulatory
mechanisms unique to human HSF1, potentially through
modulation of the TRiC complex. In support of this notion,
human HSF1 is not activated in yeast by several compounds that
enhance protein chaperone expression in yeast and mammalian
cells by promoting the accumulation of damaged and misfolded
proteins [60] (Figure S9).
Discussion
Here, we describe a novel humanized yeast high-throughput
screen for the identification of small molecule activators of human
HSF1. Utilizing this screen, we have identified HSF1A, a molecule
capable of promoting human HSF1-dependent yeast cell growth,
HSF1 multimerization in yeast, as well as HSF1-dependent
protein chaperone expression in mammalian cell culture and in
fruit flies. Human HSF1 is normally activated by cellular stress
conditions that cause proteotoxicity through protein damage. As
such, previous screens for small molecule activators of HSF1 in
mammalian cells have identified molecules that elevate protein
chaperone expression through the imposition of proteotoxic stress
conditions, such as direct protein thiol oxidation [34], thereby
disrupting protein homeostasis and resulting in protein damage. In
addition, since HSF1 is repressed through an interaction with
Hsp90, small molecule inhibitors of Hsp90 are often identified as
HSF1-activating molecules [33].
Figure 6. HSF1A is unlikely to be an inhibitor of Hsp90. (A) Yeast cells were treated with either 10 mM HSF1A, 10 mM geldanamycin, or 10 mM
radicicol and growth was assessed as in Figure 1C. (B) Purified Hsp90a was incubated with increasing concentrations of 17-AAG or HSF1A for 30 min
at 4uC and then incubated with 1 mM geldanamycin-biotin for 1 h at 4uC. (C) Geldanamycin-biotin–bound Hsp90 was captured using neutravidin-
agarose beads and analyzed by immunoblot analysis. Hsp90a was incubated with either 10 mM geldanamycin-biotin (GD-B) or 100 mM HSF1A-biotin
(HSF1A-B) and was analyzed as described in Figure 2B.
doi:10.1371/journal.pbio.1000291.g006
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human HSF1 is not yet understood, several observations suggest
that HSF1A does not activate HSF1 through the inhibition of
Hsp90 activity nor through the imposition of a proteotoxic stress.
The inability of well-established inhibitors of both mammalian and
yeast Hsp90, geldanamycin and radicicol, to promote HSF1-
dependent yeast growth suggests that HSF1A is promoting HSF1
activation in yeast independent of Hsp90 inhibition. This is
confirmed by our data showing that HSF1A does not bind to
Hsp90 and does not efficiently compete with geldanamycin for
Hsp90 binding. In addition, HSF1A was not able to promote yeast
HSF activation, also thought to be repressed by Hsp90 [61,62].
Moreover, unlike the sensitivity of acute heat shock or celastrol
treatment to DTT, HSF1A activation of HSF1 was not inhibited
by this exogenous thiol reductant, suggesting that HSF1A does not
promote HSF1 activation by inducing thiol oxidation and protein
damage.
Interestingly, our data show that HSF1A interacts with the
TRiC/CCT complex in both yeast and mammalian cell extracts,
though it remains unclear whether this interaction is direct or
indirect. In addition, it remains unclear whether or not HSF1A
affects TRiC activity. To date, no known role for TRiC in HSF1
regulation has been described. As such, further investigation is
required to ascertain whether HSF1A modulates TRiC activity
and how this might impinge on HSF1 activation. Interestingly,
TRiC chaperone activity was recently shown to be a potent
negative regulator of polyQ protein aggregation and cytotoxicity
in yeast and mammalian systems [48,63]. Since HSF1A similarly
ameliorated polyQ aggregation and cytotoxicity, our data are
consistent with a model in which HSF1A might act as a positive
regulator of TRiC activity.
Strong evidence in cellular and animal model systems of
neurodegenerative diseases associated with protein misfolding
support the idea that protein chaperones act to ameliorate the
biochemical and neurodegenerative phenotypes [5–13,48]. Al-
though elevated expression of Hsp70 or Hsp40 can significantly
suppress protein aggregation, coexpression of the two chaperones
can synergize the suppression of protein aggregation, enhance
protein solubility, and ameliorate neuronal loss as a consequence
of polyQ protein or a-synuclein expression [8,9]. Moreover, a
Figure 7. HSF1A-biotin associates with the TRiC/CCT complex. (A) Cell extracts from mouse embryonic fibroblasts were incubated with
100 mM HSF1A-biotin, and associated proteins were then purified with neutravidin-agarose beads. HSF1A-biotin-interacting proteins were resolved
by SDS-PAGE and visualized by silver staining. (B) HSF1A-biotin-interacting proteins were purified as in (A) from HeLa cell extracts and analyzed by
immunoblot analysis for Tcp1, Cct8, and Hsp90. (C) HSF1A-biotin-interacting proteins were purified as in (A) from yeast cell extracts and analyzed by
immunoblot analysis for yTcp1.
doi:10.1371/journal.pbio.1000291.g007
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in cultured cells and in mice, and enhanced the longevity of a
mouse model of polyQ-based Huntington disease [5]. Given that
HSF1 coordinately activates the expression of multiple protein
chaperones and other cytoprotective genes [64–67], HSF1
activation could be of potential therapeutic value in neurodegen-
erative diseases associated with a wide array of manifestations of
protein misfolding.
Here, we demonstrate in cultured neuronal precursor cells, and
in a fruit fly model of polyQ disease, that HSF1A can suppress the
aggregation of a polyQ protein and cytotoxicity associated with
polyQ expression. Interestingly, in both the cell culture and fly
polyQ model, the concentration of HSF1A required to reduce
cytotoxicity is significantly less than the concentration required for
maximum Hsp70 expression. Similar results have been described
for the Hsp90 inhibitor geldanamycin, which was able to rescue
cell viability in a Drosophila model of Parkinson disease at
concentrations significantly lower than that required to induce
Hsp70 expression maximally [52,68]. Together, these results
suggest that relatively small yet chronic increases in protein
chaperone expression are sufficient to significantly stabilize
misfolded polyQ proteins and thereby reduce cytotoxicity. It is
also possible that low levels of HSF1A reduce the threshold of
HSF1 activation in response to the accumulation of unfolded
proteins at physiological temperatures. This hypothesis is support-
ed by our results demonstrating that HSF1A can reduce the
temperature threshold required for HSF1 activation. Previous
studies have shown that misfolded polyQ proteins are turned over
by autophagy and ubiquitin-dependent proteosomal degradation
and that protein chaperones can impinge on both processes
[69,70]. In addition, HSF1 and protein chaperones have been
suggested to be potentiators of oncogenic transformation [71].
Although we do not yet fully understand whether HSF1A-
mediated protein chaperone expression affects these processes,
these hypotheses are currently under investigation. Given the
broad range of protein chaperone functions, the humanized yeast-
based screening results described here present a new avenue for
the identification of new classes of small molecules that could have
therapeutic efficacy, via potentially distinct mechanisms, in
neurodegenerative diseases caused by protein conformational
disorders.
Materials and Methods
Yeast Screen for Human HSF1 Activators
To screen for small molecule activators of human HSF1 in
yeast, we generated yeast strain DNY75 that expresses yeast HSF
under control of the galactose-inducible and glucose-repressible
GAL1 promoter and human HSF1 under the control of the
constitutive GPD promoter. Yeast cultures were grown overnight
to mid-log phase in SC-URA-TRP media containing 2% raffinose
and 0.01% galactose. Cultures were reinoculated to an optical
density at 600 nm (OD600)=0.0005 in SC-URA-TRP containing
4% dextrose to extinguish expression of yeast HSF. Using a
Beckman Biomek FX robot, 200 ml of the yeast culture were
pipetted into each well of a 96-well plate and supplemented with
compounds (10 mM final concentration) from a combinatorial
compound library (PPD Discovery) containing 10,440 compounds
[40] or DMSO as solvent at the same final percent volume. Cells
were incubated at 30uC for 4 d and their growth monitored
spectrophotometrically at OD600 using a Spectra Max 384 plate
reader (Molecular Devices). Chemicals promoting yeast cell
growth were selected from the library and further validated in
two additional rounds of screening. In total, we identified 33
positive-hit molecules (0.32% hit rate) able to promote human
HSF1-dependent yeast growth. Growth curve experiments were
carried out in 96-well plates. Data shown for all growth curves are
averages of four independent experiments with associated
standard deviations. High-throughput screening (HTS) assays are
usually assessed for their suitability using a statistical Z9-factor by
comparing positive and negative controls [72]. However, during
the development of this assay, we were unable to calculate a Z9-
factor to assess this assay since a positive control molecule able to
promote human HSF1-dependent growth in yeast was unavail-
able. Upon the identification of HSF1A, we reassessed the Z9-
factor using the formula Z9=12[(3sc++3sc2)/(|mc+2mc2|)],
where s=standard deviation, m=mean, c+=HSF1A, and
c2=DMSO of the growth rate of the yeast culture between
day 1 to day 4. The Z9-factor was calculated to be 0.51, indicating
that this assay is appropriate for further HTS studies.
Yeast Strains
Strain DNY75 was derived from PS145 (MATa ade2 trp1 leu2
his3 ura3 hsf1D::LEU2 Ycp50gal-yHSF1) [43] by deleting PDR5,
SNQ2, and ERG6 in successive steps using a loxP-KanMX4-loxP
deletion cassette. After deletion of PDR5 and SNQ2, the KanMX4
gene was removed by recombination via expression of the Cre-
recombinase-expressing plasmid pSH47 [73]. The KanMX4 gene
was not removed after the disruption of the ERG6 gene. For
screening of hHSF1-activating molecules, DNY75 was trans-
formed with pRS424-GPD-hHSF1 by electroporation. DNY227
was derived from DNY75 by exchanging the inducible plasmid
Ycp50GAL-yHSF1 with the constitutively expressed pRS314-
yHSF1.
Hsp90 Binding Assays
Purified Hsp90a (2 mg, Assay Designs) in Hsp90 binding buffer
(10 mM Tris, 50 mM KCl, 5 mM MgCl2, 20 mM NaMoO4,
0.01% NP40) was incubated with either GD-biotin (Biomol) or
HSF1A-biotin for 1 h at 4uC, and bound Hsp90 was then
captured by incubating with neutravidin-agarose beads for 30 min
at 4uC. The beads were washed three times in Hsp90 binding
buffer, and Hsp90 was eluted from the beads by incubating in
Laemmli Sample Buffer at 95uC for 5 min. For competition
experiments, Hsp90a was pre-incubated with either 17-AAG or
HSF1A for 30 min at 4uC prior to the addition of GD-biotin.
Identification of HSF1A-Biotin-Associated Proteins
Protein extracts were generated from mammalian and yeast cell
cultures using biotin binding buffer (20 mM HEPES, 5 mM
MgCl2, 1 mM EDTA, 100 mM KCl, 0.03% NP-40) supplement-
ed with 1% Triton X-100 and protease inhibitors. A total of 1 mg
of a whole-cell extract was incubated with 100 mM HSF1A-biotin
for 15 h at 4uC. HSF1A-biotin-associated proteins were captured
by incubating with neutravidin-agarose beads for 90 min at 4uC.
The beads were washed three times in biotin binding buffer and
the associated proteins were eluted from the beads by incubating
in Laemmli Sample Buffer at 95uC for 5 min. Proteins that co-
purified with HSF1A-biotin were resolved on a 4–20% SDS-
PAGE gel and visualized by colloidal blue or silver staining.
Protein bands were excised from the gel, and the gel slice was
subjected to in-gel digestion (detailed protocol at http://www.
genome.duke.edu/cores/proteomics/sample-preparation/), fol-
lowed by LC-MS/MS analysis using a nanoAcquity liquid
chromatograph and a QToF Premier mass spectrometer (Waters
Corp). The top three most intense multiply-charged ions from
each MS scan were interrogated by tandem MS. Raw data were
processed using Mascot Distiller v2.0 and searched against the
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www.expasy.org) using Mascot v2.2 database search engine, with
20 ppm precursor and 0.04 Da product ion tolerance. Iodoace-
tamide derivative of cysteine (fixed) and oxidation of methionine
(variable) were specified in the Mascot search. Scaffold (version
2.05.02, http://www.proteomesoftware.com) was used to validate
MS/MS-based peptide and protein identifications. Peptide
identifications were accepted if they could be established at
greater than 80.0% probability as specified by the Peptide Prophet
algorithm. Protein identifications were accepted if they could be
established at greater than 95.0% probability and contained at
least two identified peptides.
Cell Culture
Mammalian cell lines used in this study were HSF1
+/+ and
hsf1
2/2 MEF cells [74], HeLa cells, and inducible PC12 cells
expressing httQ74-GFP [49]. For a Drosophila cell line, we used S2
cells. HSF1
+/+ and hsf1
2/2 MEFs used in this study have been
described elsewhere [41]. MEFs were maintained on DMEM
supplemented with 10% fetal bovine serum (FBS), 0.1 mM
nonessential amino acids, 100 U/ml penicillin/streptomycin,
and 55 mM 2-mercaptoethanol. HD-Q74 PC12 cells were
previously described [49] and were maintained on DMEM
supplemented with 5% Tet-approved FBS, 10% horse serum,
100 mg/ml G418, 75 mg/ml Hygromycin B, and 100 U/ml
penicillin/streptomycin. For all experiments, the cells were washed
once in PBS and then shifted with serum-free OPTI-MEM
medium (Invitrogen) supplemented with 100 U/ml penicillin/
streptomycin, 0.1 mM nonessential amino acids, and 55 mM2 -
mercaptoethanol immediately prior to the addition of HSF1A.
The cells were maintained in serum-free media throughout the
course of experiments. S2 cells were maintained and assayed in
Schneider’s Drosophila medium supplemented with 10% FBS.
EGS Cross-Linking and Immunoblotting Analysis
Protein extracts were generated from cell cultures using cell lysis
buffer (25 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 1 mM EDTA) supplemented with protease inhibitors.
Protein concentrations were quantified using the BCA assay and
10–20 mg of total protein was resolved by SDS-PAGE, transferred
to a nitrocellulose membrane, and proteins of interest detected by
immunoblot analysis following standard procedures. For HSF1
phosphorylation experiments, protein extracts were isolated either
in the presence or absence of the Halt phosphatase inhibitor
cocktail (Pierce). For nuclear localization experiments, nuclear and
cytoplasmic fractions were isolated using the NE-PER kit (Pierce).
HSF1 multimerization state was assessed using the amine-specific
cross-linker ethylene glycol bis-succinimidyl succinate (EGS)
(Pierce). DNY227 was grown in the presence of DMSO or
20 mM HSF1A for 18 h to a final OD600=0.8. Cells were washed
once with water and extracts prepared by glass bead lysis in
HEGNT buffer (20 mM HEPES [pH=7.5], 1 mM EDTA, 10%
glycerol, 0.4 M NaCl, 1% Triton X-100). Protein extracts (50 mg)
were incubated with either DMSO or 0.5 mM EGS for 30 min at
24uC. The cross-linking reaction was quenched via the addition of
50 mM glycine/0.025 mM Tris (pH=7.5) for 15 min at 24uC.
Proteins were fractionated through a 7.5% SDS-polyacrylamide
gel and analyzed by immunoblotting with a polyclonal antibody
specific to human HSF1. Primary antibodies used were anti-
Hsp90a (9D2, Assay Designs), anti-Hsc70/Hsp70 (W27, Santa
Cruz Biotechnology), anti-Hsp25 (SPA-801, Assay Designs), anti-
c-fos (6-2H-2F, Santa Cruz Biotechnology), anti-SOD1 (SOD101,
Assay Designs), anti-dHsp70 (dN-12, Santa Cruz Biotechnology),
anti-actin (AB-5, BD Transduction), anti-TCP1 (2B2-D6, AB-
NOVA), anti-CCT8 (B02, ABNOVA), anti-TCP1 (91a, Assay
Designs for immunoblot analysis of yeast Tcp1), and anti-GFP
(SC-8334, Santa Cruz Biotechnology) used according to the
provider’s instructions and an affinity-purified rabbit polyclonal
anti-HSF1 antibody directed against the HSF1 sequence
ISLLTGTEPHKAKDPTVS, which cross reacts with mouse,
rat, and human HSF1 was used at a 1:1,000 dilution.
RNA Blotting
MEF Cells were seeded into 10-cm plates (3610
6 cells/plate)
and exposed to either DMSO or HSF1A for 6 h or heat shocked
at 42uC for 2 h followed by a 15-h recovery at 37uC. mRNA was
isolated from cells using the RNeasy Kit (Qiagen) according to the
manufacturer’s recommendations. Total RNA (10 mg) was ana-
lyzed as described [64], utilizing mHsp70-1 cDNA as a template
for probe generation. An oligonucleotide complementary to mouse
18S rRNA was used as a probe for loading.
b-Galactosidase Assays
For b-galactosidase assays, yeast strain DNY227 transformed
with YEp24-SSA3p-LacZ was grown to mid-log phase in SC-
URA medium and treated with DMSO or 20 mM HSF1A for 6 h.
For comparison, the yeast cells were heat shocked at 39uC for 3 h.
b-Galactosidase activity was measured as previously described
[75]. Data shown are averages of three independent experiments
with associated standard deviations.
Fluorescence Microscopy
PC12 cells expressing httQ74-GFP were seeded into 6-well glass
bottom plates (6610
5 cells/well), treated with 10 mM HSF1A or
DMSO for 15 h and expression httQ74-GFP induced by the
addition of 1 mg/ml doxycycline. Fluorescence was analyzed using
a Zeiss Axio Observer fluorescence microscope and images
deconvoluted with MetaMorph software. For quantification of
fluorescence microscopy analysis, approximately 800 cells were
counted for each treatment. The number of cells containing
aggregates was calculated as a percentage of the total number of
cells counted. The data shown are derived from four independent
experiments and are given as averages with associated standard
deviations. Statistical significance was calculated with Prism 4
using the unpaired Student t-test. **p,0.01; ***p,0.001.
Cytotoxicity Assays
PC12 cells seeded into a 96-well plate (5610
4 cells/well) were
treated with increasing concentrations of HSF1A for 15 h, at
which time httQ74-GFP expression was stimulated by incubation
in the presence of 1 mg/ml doxycycline for 5 d. Cell viability was
assessed via the XTT viability assay (Roche) per the manufactur-
er’s recommendations. ***p,0.001.
Protein Aggregation Analysis
PC12 cells were seeded (5610
5 cells/well) into a 6-well plate
and treated with either DMSO or 10 mM HSF1A for 15 h, at
which time expression of httQ74-GFP was induced via the
addition of 1 mg/ml doxycycline followed by a 48 h incubation.
Extracts were prepared, and soluble and insoluble fractions were
separated by centrifugation and analyzed by immunoblotting as
previously described [5].
Drosophila Experiments
The fly stocks gmr-GAL4 and UAS-MJDtr-Q78
strong were
previously described [51]. All fly crosses were carried out at 25uC
in a temperature- and humidity-controlled incubator. Fly food was
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supplemented with either DMSO, 400 mM HSF1A, or 5 mM 17-
AAG. gmr-GAL4 virgins were crossed to UAS-MJDtr-Q78
strong
males on supplemented food; all progeny from the crosses carried
one copy each of the gmr-GAL4 and UAS-MJDtr-Q78
strong
transgenes. Progeny were allowed to age for approximately 24 h
before imaging, and fly head images were captured using an
Olympus SZX7 microscope and DP71 camera. For induction of
Hsp70 expression, W
1118 flies were maintained on food supple-
mented with either DMSO, 5 mM HSF1A, or 0.15 mM
geldanamycin for 3 d. Total protein was extracted from five to
ten flies and assayed for Hsp70 expression by immunoblot
analysis.
In order to test whether HSF1 was required for HSF1A-
dependent amelioration of MJD-induced cytotoxicity the hsf
4 allele
[54] was recombined onto a chromosome carrying the UAS-
MJDtrQ78
strong transgene. The recombinant hsf
4, UAS-
MJDtrQ78
strong flies were then crossed to gmr-Gal4 flies and
maintained at 25uC. Growth at 25uC was semipermissive for hsf
4
activity, allowing hsf
4-expressing flies to develop similarly to wild-
type flies but essentially ablating HSF activity in adult flies [54].
Supporting Information
Figure S1 HSF1C activates human HSF1 function in
yeast and mammalian cells. (A) Structure of HSF1C. (B)
Yeast cells (DNY75) expressing wild-type human HSF1 were
supplemented with 10 mM HSF1A, 10 mM HSF1C or DMSO,
and grown in 96-well plates for 4 d. Growth was monitored by
measuring OD600. (C) HSF1
+/+ MEFs were treated with DMSO,
100 mM HSF1A, or 100 mM HSF1C for 15 h or heat shocked for
2 h at 42uC followed by a 15-h recovery. Total protein was
analyzed for Hsp70 by immunoblotting. GAPDH serves as a
loading control.
Found at: doi:10.1371/journal.pbio.1000291.s001 (0.59 MB TIF)
Figure S2 HSF1A promotes expression of Hsp70 in
human cells. HeLa cells were treated with increasing concen-
trations of HSF1A for 15 h or heat shocked for 2 h at 42uC
followed by a 15-h recovery. Total protein was extracted and
analyzed for Hsp70 expression by immunoblotting. GAPDH
serves as a loading control.
Found at: doi:10.1371/journal.pbio.1000291.s002 (0.46 MB TIF)
Figure S3 HSF1A promotes Hsp70 expression at low
micromolar concentrations. PC12 cells were incubated with
increasing concentrations of HSF1A for 72 h, and Hsp70
concentration was measured as a function of total protein
concentration by ELISA (Assay Designs).
Found at: doi:10.1371/journal.pbio.1000291.s003 (0.18 MB TIF)
Figure S4 HSF1A-dependent activation of human HSF1
in yeast is not repressed by DTT. DNY75 cells were treated
with 10 mM HSF1A in the absence or presence of 250 mM DTT
and grown in 96-well plates for 4 d. Growth was monitored by
measuring OD600.
Found at: doi:10.1371/journal.pbio.1000291.s004 (0.26 MB TIF)
Figure S5 HSF1A does not reduce polyQ toxicity in flies
carrying the hsf
4 allele. hsf
4, UAS-MJDtrQ78 recombinant flies
were crossed to gmr-GAL4 flies in the chronic presence of food
supplemented with DMSO or 400 mM HSF1A and maintained at
25uC, a semipermissive temperature for hsf
4 activity. No reduction
in polyQ-related phenotypes is observed in response to HSF1A
treatment, suggesting that full HSF activity is required for HSF1A-
dependent amelioration of polyQ induced phenotypes.
Found at: doi:10.1371/journal.pbio.1000291.s005 (2.01 MB TIF)
Figure S6 Geldanamycin and radicicol promote acti-
vation of SSA3-lacZ. Yeast strain DNY227, harboring the
yHSF1-dependent SSA3-lacZ reporter gene, was exposed to
DMSO, 10 mM geldanamycin (GD), or 10 mM radicicol for
3 h upon which time reporter gene activation was assessed by
b-galactosidase activity assays.
Found at: doi:10.1371/journal.pbio.1000291.s006 (0.26 MB TIF)
Figure S7 (A) Structure,
1H/
13C, and EIMS data of
HSF1A. (B) Structure,
1H/
13C, and EIMS data of HSF1A-
biotin.
Found at: doi:10.1371/journal.pbio.1000291.s007 (0.62 MB TIF)
Figure S8 HSF1A does not activate yeast HSF. Yeast cells
expressing the yHSF1-dependent SSA3-lacZ reporter gene were
grown at 30uC and exposed to 20 mM HSF1A or DMSO for 6 h
or heat shocked at 39uC for 3 h. Reporter gene activation was
assessed by b-galactosidase activity assays.
Found at: doi:10.1371/journal.pbio.1000291.s008 (0.29 MB TIF)
Figure S9 Human HSF1 is not activated in yeast by
proteotoxic agents. Yeast cells were treated with either HSF1A,
resveratrol (RV), azetidine (AZC), TPCK, TLCK, puromycin
(PM), or menadione (MD) at a concentration of 10 mM and for
4 d. Growth was monitored by measuring OD600.O D 600 readings
at day 4 are shown.
Found at: doi:10.1371/journal.pbio.1000291.s009 (0.25 MB TIF)
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